Background: Although Hodgkin's disease can be treated successfully, its long-term survival rate has yet to be definitely established. We compared the long-term mortality rate of patients diagnosed as having Hodgkin's disease with that of the general population.
Introduction
Having been considered an incurable disease for many years, Hodgkin's disease first began to be successfully treated about 25 years ago [1] . The definition of cure of Hodgkin's disease accepted at that time [2, 3] , based on a disease-free survival of over one decade after treatment and a mortality rate similar to that of the normal population of the same age and sex, still applies. The development of radiotherapy techniques together with modern chemotherapy have made Hodgkin's disease almost curable, as shown by the fact that around 90% of patients in favourable stages I and II and 70% of all patients are considered to be cured [4] [5] [6] [7] . Although there is little evidence of specific causes of mortality among patients diagnosed with Hodgkin's disease [8] , the criterion used for cure refers to tumour progression-free survival. It is assumed that patients cured of Hodgkin's disease and followed for a long period with no evidence of relapse have survival rates similar to those of the general population, despite the fact that only a few studies have compared causes of death between these patients and the general population of the same sex and age [5, 9] .
In this study, our aim was to determine the long-term survival of patients with Hodgkin's disease after treatment and compare it with the expected survival of the general population. Our purpose was to test the hypothesis of an eventual definitive cure for Hodgkin's disease.
Patients and methods

Population study
Because the university hospital 'Clinica Puerta de Hierro' has been a national reference centre for lymphomas since the 1960s, we proposed to retrospectively identify all patients diagnosed with Hodgkin's disease since 1967, the year when storage of complete patient clinical records was initiated, to 1993. To be considered for inclusion, all patients had to have had a pathologically-confirmed diagnosis of Hodgkin's disease. In the 48 cases in which the diagnosis was uncertain, the pathology findings were reviewed and 19 cases in which the diagnosis remained unclear were excluded. The histopathological classification was based on the Lukes and Butler criteria [10] . Those patients diagnosed according to the Jackson and Parker classification and those in whom the subtype could not be determined were categorized as having non-specified Hodgkin's disease. A total of 477 patients were studied.
Measurement of variables
The classification by stage was based on the criteria defined at the Rye meeting in 1972 and subsequently modified at the Ann Arbor [11] and Cotswolds [12] meetings. For statistical purposes, the stages were designated 'favourable' (stages IA and IIA) or 'unfavourable' (stages IB, IIB, III and IV). The chemotherapy treatment consisted of the combinations MOPP [13] (mechlorethamine, vincristine, procarbazine and prednisone), ABVD [14] (doxorubicin, bleomycin, vinblastine and dacarbazine), or a mixture of the two. The radiotherapy treatment was applied according to the recommendations of Kaplan [15] and adapted to the needs of our hospital by Aragon et al. [16] . The following criteria were used to define the type of response to treatment: a complete response was defined as the disappearance of all evidence of disease, both clinical and radiological, for at least four weeks after the end of treatment. In instances of a residual mass, response was defined as complete if the mass was stable for at least one month after the end of radiotherapy treatment or for the duration of two complete chemotherapy cycles, and the patient had no other clinical or analytical signs of lymphoma activity [17] . An incomplete response was defined as any response that was not complete: either some kind of partial response or none whatsoever. A relapse was defined as the confirmation of active disease, either by histology or radiology, occurring at least four weeks after the achievement of a complete response. When a patient died during the initial treatment, he or she was excluded from the response classification. The cause of death was classified as 'primary tumour' if it was directly related to Hodgkin's disease, 'secondary tumour' if it was due to a secondary neoplasm, and 'other'. All of the clinical information was extracted from the clinical records and from the 40 autopsies. To ascertain the vital status, all patients were contacted and invited to come to the clinic. All patients who could not be contacted were considered lost to follow-up. The calendar period was divided into three equal periods chosen a priori, 1967-1975, 1976-1984 and 1985-1993 .
Main outcome variable
The outcome variable was the standardised mortality ratio (SMR), which is the ratio between the number of deaths observed in the cohort and the number of cases expected if the cohort had the same mortality rates as the general population. This measure of association is interpreted as the ratio of two standardised rates, the one from the cohort studied and the one from the general population, when the age and sex distribution of cohort of patients with Hodgkin's disease are used as the standard. If the estimated SMR is equal to 1, the study group is considered to have had a mortality similar to that of the general population, whereas if the estimated SMR is greater than 1, the study group is considered to have had a mortality rate higher than that of the general population as many times as the number of units of the estimated SMR.
To arrive at the follow-up time for each subject, the time interval between the date of diagnosis and the date of death, the date the patient was lost to follow-up, or 31 December 1993, whichever came first, was computed in years. The follow-up times for all subjects were stratified according to sex, age, five-year age groups, and calendar time from 1967 to 1993. In 67 cases (14%) in which the day and month of birth were missing, 1 July was the date used. The total number of person-years was computed for each of these strata using a statistical programme.
We used the Spanish population for comparison. The Spanish annual mortality rates from 1975 to 1993, the last year for which data were available, were provided by the Instituto Nacional de Estadistica, stratified by sex and age groups (less than one year of age, one to four years, and then five-year age groups from 5-9 up to 75-79, plus a group of 80 years and over, until 1979 and two groups, from 80-84 and 85 and over, from 1980 on) [18] . From 1967 to 1974 the mortality rates were computed by the authors with data taken from two sources, the Statistical Annuals from the Instituto Nacional de Estadistica, which gave the births occurring annually in Spain and the deaths classified by sex and five-year age groups up to 90 years, and the population censuses of 1960, 1970, and 1981 , classified by sex and five-year age groups up to 15 years and 10-year age groups up to 65 years. As there were no accurate data on migratory movements in that period, we estimated the population for the years between censuses in each age stratum as the proportional part of the difference between censuses corresponding to the number of years passed since the previous census. The deaths not classified by age in the Statistical Annuals (0.51%) were assigned to all strata following weights proportional to the number of deaths in each stratum. For each sex and age stratum, mortality rates were computed dividing the estimated total deaths over the estimated population. For the period 1967-1974, mortality rates are shown in five-year age groups up to 15 years, in 10-year age groups up to 65 years and a group of 65 years and over.
In each stratum, the total expected deaths for the general population were determined by multiplying the person-years by the corresponding mortality rate for that stratum. The total expected cases for the study population as a whole were determined by adding together the expected cases for each stratum.
For each standardised mortality ratio, a 95% confidence interval (95% CI) was computed using the ratio between the corresponding limits of the Poisson distribution of the number of observed cases and the number of expected cases [19] . When the number of observed cases exceeded 100, the limits of the Poisson distribution were extrapolated according to the Freeman and Tukey method [20] . For each standardised mortality ratio, hypothesis testing was performed using the Byar approximation to the exact Poisson test [21] ,
The excess of deaths, the difference between the number of observed deaths in the study group and the number of expected deaths in the general population, was also computed and reported as the number of additional deaths per 100 person-years.
Cumulative survival probability
The survival probability in the cohort as a whole, overall and stratified by sex, was computed by the product-limit estimate method. For each median, 95% confidence intervals were calculated [22] . To compare the cohort survival probability to that of the general population, we used the life table method [23] . The partial and total survival probabilities were estimated for each year after the date of diagnosis, taking into account the number of patients alive at the beginning of the year in question, the number of patients who died during the succeeding year and the number of patients lost to follow-up during that period. The method of transformation to a logarithmic scale was used to compute the standard errors of the annual partial and total probabilities [22] . The cumulated survival probability curves, with their corresponding 95% confidence limits, were then compared with the expected cumulative survival probability from the general population standardised to an age and sex distribution similar to that of the studied cohort. The annual probability of death in the general population was first calculated by dividing the number of expected deaths over the total number of person-years observed for each year. Then, the probability of survival was calculated as the complement of the probability of death and the cumulative survival probability as the product of each annual survival probability. Finally, relative survival estimates, the ratios between the observed and the expected cumulative probabilities at different years of follow-up and their corresponding confidence intervals were computed. The time when relative survival becomes constant indicates the moment when deaths due to the disease under study are no longer recorded [24] .
Multivariate statistical analysis
To study the age-and sex-adjusted influence of disease staging and calendar period on mortality, we performed an SMR multivariate analysis following a Poisson multiplicative model, OBS,vt = EXP,* • SMR • exponential (x/tP), or, in other terms, Log OBS,* = Log EXP,* + u + x J;t p, where OBS/t is the expectancy of the number of deaths for each stratum of sex, age (/) and the exposed or studied variable (k), EXP is the number of expected deaths for each stratum of sex and age (/) in the general population after application of the population mortality rates, u denotes the SMR logarithm in the reference group of the exposed variable, Xy^ is the configuration of variables in stratay and k, and p indicates the parameters for the variables under study, (37) 94 (20) 143 (30) 117 (25) 98 (21) 25 (5) 109 (23) 175 (37) 193 (40) 85 (18) 8 (2) 139(29) 61 (13) 56 (12) 62 (13) 16 (3) 50 (11) 437 (92) 36 (8) 138 (29) 146 (31) 170 (36) 86 (18) Because of rounding up the total of some percentages is not 100. In the 'Response to treatment' section, four cases were missing. The percentages in the death causes are calculated over the 133 deaths.
age, sex, disease staging and calendar period, whose exponentiation multiplies the SMR in the reference exposure group. Since comparisons between two or more SMRs may be misleading if the specific age rates for the cohorts to be compared are not proportional to the reference population rates [19, 25] , we indirectly checked that condition with the goodness of fit of the model. The final model included all of the variables studied, sex, age, stage and period, as independent variables.
The goodness of fit was checked through the deviance (G 2 ), the Pearson residuals (x 2 ), the addition of interactions, and the graphical analysis of residuals [19, 26] . The chi-squared likelihood ratio test was used to assess whether a variable should be included in the model. Survival rates by sex were compared using the log-rank test. The level of statistical significance was set at 0.05 for all comparisons. All statistical analyses were carried out with the statistical software GLIM 4.0 [27] .
Population study
We studied 477 patients, with a median follow-up time of 8 years (range 0-26 years). The follow-up was complete for 427 (89.5%), although for 58 cases known to be alive the last information was obtained between 1992 and 1993. The median age at diagnosis was 30 years (range 4-85). The sex ratio (male: female) at diagnosis was 1.7:1. Of the total group of patients, 133 (28%) died (Table 1) 
Standardised mortality ratios
In the overall analysis, the SMR for patients with Hodgkin's disease was 10.8 (95% CI: 9.0-12.8, P < 0.0001). The SMRs were consistently high for both sexes ( Table 2 ). The excess of deaths per 100 person-years in the overall sample of Hodgkin's disease patients was 3.2 ( Table 2 ). The analyses by five age strata (under 20, 20-29, 30-39, 40-59 and 60 years or over) showed SMRs significantly greater than 1 in all age groups; they tended to diminish with age whereas the excess of deaths increased slightly with age ( Table 3) .
The SMR was higher in the 'unfavourable' stages IB, IIB, III and IV than in the 'favourable' stages IA and IIA (Table 4) . The SMRs and excess of deaths declined with calendar periods under study, 1967-1975,1976-1984, and 1985-1993 (Table 5 ).
In the analysis of long-term mortality, in five-year periods after diagnosis, the SMRs and excess of deaths were consistently higher than 1 in all periods, even 20 years after diagnosis (Table 6) . We compared the mortality unrelated to Hodgkin's disease with the general population assuming that, given the low incidence of Hodgkin's disease in the general population, its contribution to the general mortality rates is negligible. A total of 84 patients died of causes unrelated to Hodgkin's disease and 12.4 were expected, giving an SMR of 6.8 (95% CI: 5.4-8.4, P < 0.0001, excess of deaths: 1.9/100 person-years). In men, the SMR was 5.8 (95% CI: 4.4-7.5, P < 0.0001) and in women, it was 10.9 (95% CI: 7.0-16.1, P < 0.0001). Abbreviations: No -total number of subjects; O -observed deaths; E -expected deaths; SMR -standardised mortality ratio; CI -confidence interval; P -probability. Abbreviations: No -total number of subjects; O -observed deaths; E -expected deaths; SMR -standardised mortality ratio; CI -confidence interval; P -probability. The excess of deaths is expressed in 100 person-years. 
Cumulative survival probability
The estimates of the overall survival probability with their 95% CI were always lower than the expected survival probability of the general population ( Figure 1 
Results of statistical modelling
Age over 40, diagnosis before 1985 and unfavourable stages were risk factors for increased mortality in Hodgkin's disease when compared to the general population in both the univariate and multivariate analyses (Table 7) . Female sex, a risk factor for mortality in the univariate analysis, was no longer a risk factor in the multivariate analysis when age, calendar period and disease staging were included in the model. Figure 1 . Cumulative probability of annual survival for the cohort of patients with Hodgkin's disease when compared with the estimated cumulative probability for the general population.
Discussion
Despite the advances introduced in the treatment of Hodgkin's disease over the past three decades, in our patients with Hodgkin's disease we found the rate of mortality to be more than 10-fold higher than that of the general population and there were over 3 deaths more per 100 person-years. This higher mortality rate was observed in both men and women, all age groups, all stages of disease, and every calendar period; in particular, younger ages, unfavourable stages and earlier periods had the highest rates. The higher mortality was sustained throughout the entire follow-up period, even after 20 years, and it never stabilised. As only 37% of deaths were due to the primary tumour, the excess of mortality must also have been caused by secondary tumours and other factors, which explains the almost seven-fold increase in the risk for death. The reasons for this excess are still uncertain [28] , although there is some evidence of a higher incidence of second malignant neoplasms [29, 30] , thought to be related either to the toxicity of treatment or to intrinsic host factors linked to the initial Hodgkin's disease, and sparse evidence for a higher incidence of cardiovascular complications [31] [32] [33] . The direction of our findings is consistent with other studies comparing the long-term mortality of patients with Hodgkin's disease with that of the general population [5, 34] but we found an overall standardised mortality ratio 1.5 higher than the figure of 7.09 reported previously by the International Data Base on Hodgkin's Disease (IDHD) [5] . Our findings also agree with the observation of a decrease in mortality from Hodgkin's disease in Europe in recent decades [35, 36] . In contrast to the IDHD study, which affirms that 67% of patients die of disease progression, in our study we found it to be the cause of death in only 37%. The reasons for this discrepancy are unclear, although the proportion of ascertainment by necropsy and the coding system of causes may have been different. Our study has some strengths. The proportion of patients lost to follow-up was quite low (3.8%). Moreover, the follow-up time was very long, spanning the entire period since Hodgkin's disease was diagnosed and treated effectively. Furthermore, our study helps to correctly interpret the influence of some factors on mortality when a population approach is taken. While men seem to have a worse prognosis than the women in the cohort when their mortality rates are compared to those of the general population, both men and women with Hodgkin's disease have the same relative increase in mortality as their counterparts in the general population, for men usually have higher mortality rates than women. Likewise, although as compared with patients with Hodgkin's disease under 20 years of age, older patients have an increased risk of dying, especially those aged from 20 to 60, when compared with the general population, the relative risk of mortality is the same up to 40 years of age and begins to decline for those over 40, probably because of competing causes of death. Finally, our study shows that, when analysed simultaneously, age, sex, disease stage and calendar period all play a role in increasing the risk of death in the general population.
This study has several limitations. Firstly, the sample studied may not be representative of the population of patients with Hodgkin's disease since it is not taken from a population-based cancer registry. Although we believe that Hodgkin's disease is usually diagnosed and treated in hospitals and is not frequently missed, each hospital may have special characteristics with respect to social class, age, sex or health care received that might to some extent affect prognosis. Moreover, as our hospital has been a reference centre for Hodgkin's disease for many years, other centres may have referred those patients with worse prognoses to ours. However, the age, sex and disease stage distribution in our sample did not differ from the large cohorts reported so far [5] . In our cohort, the complete response rate after the first treatment was 92% for the whole sample, slightly higher than in the IDHD (87%) [5] . We found a relapse rate of 29%, similar to that in other reports [37] [38] [39] [40] . Secondly, the data collection was retrospective, which may have caused some misclassification. In 4% of patients, we could not identify a precise histopathological type despite the review of preparations, although other authors have found percentages of uncertainty as high as 19% [41] . To reduce these problems, the diagnosis and disease stage were determined in accord with well established criteria. Thirdly, the mortality rates during the first 8 years studied were provided for 10-year age intervals instead of the usual intervals of 5 years. This may have affected the assumption underlying the life-table method of equal risk of death within each interval. In addition, the lack of accurate data on population migration during the years between censuses may have biased the estimates of population mortality rates. However, the consistency of our findings across all age groups and of the decreasing time trend suggest that these inaccuracies should not have had a strong influence on the results. Lastly, only a few patients were followed for 20 years or longer. Nevertheless, the standardised mortality ratio in these patients was still higher than in the general population.
In conclusion, our findings do not support the hypothesis that there will ultimately be a definite cure for Hodgkin's disease, and although the rate of mortality tends to diminish over time, it is still quite high. This excess of mortality could be due in part to the treatment administered, and further studies on the causes of the long-term mortality may shed light on identifying potential preventable factors for death.
